相关临床试验
19
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
10.5%
已完成
10
52.6%
尚未招募
2
10.5%
招募中
5
26.3%
暂无批准数据
- South Korea lowered the national health insurance reimbursement rate for generic drugs to 45 percent of the original drug's price, down from 53.55 percent, effective Aug. 1. - Industry groups estimate the overhaul could result in as much as 3.6 trillion won in lost sales and 14,800 fewer jobs across the pharmaceutical and biotech sector. - Korean drugmakers including Ildong Pharmaceutical and Chong Kun Dang have declared emergency management systems, consolidated sales organizations, and cut R&D budgets in response. - The government designed the cuts to reduce reliance on generics and encourage innovation, offering preferential rates of 60 percent and 50 percent to innovative and quasi-innovative companies.
- Samsung Biologics returns for its 14th consecutive year, showcasing 845,000 liters of total manufacturing capacity and its newly acquired Rockville, Maryland plant. - Celltrion marks its 17th appearance with a dedicated AI zone, promoting AI-driven drug discovery, antibody conjugates, and multispecific antibodies as next-generation growth engines. - For the first time, BIO International Convention hosts an official Korea-focused session titled "Korea Rising: Don't Be Late to Asia's Next Innovation Hub." - Over 20,000 attendees from more than 70 countries are expected, with 51 Korean companies presenting pipelines and platform technologies at the KoreaBio country pavilion.
- Ildong Pharmaceutical will resubmit its application for Ensitrelvir, an oral antiviral drug for COVID-19, after strengthening clinical data. - The resubmission will include findings from Shionogi's global clinical trial, SCORPIO-PEP, evaluating Ensitrelvir for post-exposure prophylaxis. - Ildong's decision aligns with Shionogi's global strategy, which includes pursuing approvals from the FDA and EMA for Ensitrelvir. - The company voluntarily withdrew its previous application to the Ministry of Food and Drug Safety to incorporate the new data.
- Bridge Biotherapeutics' BBT-877, a first-in-class autotaxin inhibitor, is undergoing Phase 2 trials with data expected in April, showing promising safety and efficacy. - Daewoong Pharmaceutical's Versiporocin (DWN12088), targeting PRS protein action, is in Phase 2 trials and has received FDA and EMA rare drug designations, aiming for completion in 2025. - Ildong Pharmaceutical is developing IL1512, a CXCR7-selective agent, set to enter GLP toxicity testing, while Hanmi Pharmaceutical's HM15211 shows promise in preclinical studies for IPF. - The IPF treatment market is projected to grow from $4.6 billion to $7 billion by 2030, driven by unmet needs and the pursuit of first-in-class and best-in-class therapies.
